SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.13), in-line with the analyst estimate of ($2.13). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.